Emendo’s CRISPR-based technology provides an end-to-end platform capable of moving novel gene editing treatments from the initial stage of target indication, through drug composition, and to commercialization with scale and speed. We’ve brought together a collaborative world-class team of more than 90 computational and molecular biologists, protein engineers, RNA guide designers and other key experts who understand the complex nature of gene editing-based drug discovery.
Our expertise spans the entire innovation pathway, from discovery to lead optimization to development and on through drug composition and commercialization. At Emendo, we can incorporate gene editing into your therapeutic development strategy, to tackle the most complex indications, to identify target genes and optimize the most elegant and effective gene editing strategies. Our goal is not just to provide our partners with novel nucleases, but to streamline the discovery-optimization-development process toward an effective human therapeutic product.